Best dim products

3,3'-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans

Chemopreventive properties of 3,3'-diindolylmethane in breast cancer: evidence from experimental and human studies

Chemopreventive properties of 3,3′-diindolylmethane in breast cancer: evidence from experimental and human studies

Cite Share Favorites Permissions RESEARCH PAPER: PROSTATE CANCER The potential efficacy of 3,3′-diindolylmethane in prevention of prostate cancer development

3,3'-diindolylmethane exerts antiproliferation and apoptosis induction by TRAF2-p38 axis in gastric cancer

3,3′-Diindolylmethane Modulates Estrogen Metabolism in Patients with Thyroid Proliferative Disease: A Pilot Study

3,3'-Diindolylmethane suppresses high-fat diet-induced obesity through inhibiting adipogenesis of pre-adipocytes by targeting USP2 activity

3,3-Diindolylmethane (DIM): a nutritional intervention and its impact on breast density in healthy BRCA carriers. A prospective clinical trial

3,39-Diindolylmethane Ameliorates Staphylococcal Enterotoxin B–Induced Acute Lung Injury through Alterations in the Expression of MicroRNA that Target Apoptosis and Cell-Cycle Arrest in Activated T Cells

Molecular Simulation Studies of 3,3'-Diindolylmethane as a Potent MicroRNA-21 Antagonist

3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivo

3,3'-Diindolylmethane (DIM) induces a G(1) cell cycle arrest in human breast cancer cells that is accompanied by Sp1-mediated activation of p21(WAF1/CIP1) expression

Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer

A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen

Dietary bioactive diindolylmethane enhances the therapeutic efficacy of centchroman in breast cancer cells by regulating ABCB1/P-gp efflux transporter

3,3'-Diindolylmethane nanoencapsulation improves its antinociceptive action: Physicochemical and behavioral studies

Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells

Low levels of 3,3'-diindolylmethane activate estrogen receptor α and induce proliferation of breast cancer cells in the absence of estradiol